Scientists from Nankai University Tianjin and Accendatech Technology Co. Ltd. have identified a majusculamide D derivative found to be useful for the treatment of cancer.
Henan Normal University and Henan Zhiwei Biological Engineering Co. Ltd. have discovered macrocyclic compounds acting as neurotrophic tyrosine kinase receptors (TRK) and/or proto-oncogene tyrosine-protein kinase ROS (ROS1; MCF3) and/or hepatocyte growth factor receptor (HGFR; MET) and/or macrophage colony-stimulating factor 1 receptor (CSF1R; CD115; c-Fms) and/or ALK tyrosine kinase receptor inhibitors found to be potentially useful for the treatment of cancer and pain.
Uniquest Pty Ltd., the commercialization company of the University of Queensland, has entered into an exclusive license agreement with the Ellison Medical Institute (EMI) to develop and commercialize the University of Queensland’s QED-203 for metastatic castration-resistant prostate cancer.
Researchers from Convalife Pharmaceuticals Co. Ltd. and Zhejiang Convalife Pharmaceutical Co. Ltd. have described dual CDK4/cyclin D1 and cyclin-dependent kinase 9 (CDK9) inhibitors reported to be useful for the treatment of cancer and inflammatory disorders.
Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has disclosed heterocyclic compounds and their antibody-drug conjugates reported to be useful for the treatment of cancer.
Due to the availability of drugs targeting histone acetylation and associated reader proteins, the equilibrium of histone acetylation and deacetylation has attracted attention in multiple myeloma as a potential therapeutic target. Therefore, the identification of novel predictive biomarkers for multiple myeloma patient selection for epigenetic therapies is urgently needed.
Advanced penile cancer (PeCa) is a rare cancer affecting the genitourinary tract with a 5-year survival rate of about 10% when metastatic. First-line therapies achieve objective response rates of 40%-50%, while immunotherapy has not been established.
RSS
